Stichting Vu-vumc

Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg

Cornelis Lammert Verweij

Paul-Peter Tak

Elisabeth Geertruida Maria Baarsen Van

Saskia Stahlecker-Voslamber

Chris Hubert Polman

Elisabeth Geertruida Maria Van Baarsen

The invention relates to methods for predicting a clinical response to B-lymphocyte inhibiting or depleting therapies (BCIDT) using expression levels of genes of the Type I INF pathway. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with B-lymphocyte inhibiting or depleting therapy. More in particular, the invention relates to a method for prognosticating the clinical response of a patient to treatment with a soluble BCID or TCID agent, said method comprising the steps of obtaining at least two samples from said patient wherein a first sample has not been exposed to a soluble BCID or TCID agent and wherein at least a second sample has been exposed to a soluble BCID or TCID agent, determining the level of an IFN-I type response in said at least two samples, comparing the level of the IFN-I type response in said first sample with the level of the IFN-I type response in said at least second sample and prognosticating said clinical response from said comparison.

Growing community of inventors

Abcoude, Netherlands

Cornelis Lammert Verweij